The global genome editing market size was estimated at USD 11.37 billion in 2025 and is projected to reach USD 39.81 billion by 2033, growing at a CAGR of 17.03% from 2026 to 2033. This growth can be attributed to the success in preclinical models driving the demand for genome editing therapeutics, rising competition among market participants for business development, technological advancements in gene editing technologies, and increasing adoption in agricultural biotechnology.
The COVID-19 pandemic had a significant impact on the market, causing disruptions in several aspects of the market including clinical trial disruptions, supply chain challenges, and stringent regulations. Manufacturing & supply chains were also affected by lockdown measures, travel restrictions, and reduced workforce, leading to delays in the production & distribution of gene therapy products. Despite these challenges, companies in the genome editing industry have adjusted to the new normal by implementing adaptive measures and are expected to recover from the impact of COVID-19. The pandemic accelerated R&D activities in gene alteration technologies, specifically in response to the urgent need for effective treatments and vaccines for COVID-19. For example, researchers at Nanyang Technological University developed the VaNGuard (Variant Nucleotide Guard) diagnostic test in March 2021, which has the capability to detect SARS-CoV-2 strains with mutations. This advancement is anticipated to leverage the utilization of CRISPR genome editing technology.
The rapid evolution of CRISPR-based tools has significantly led to the expansion of the genome editing industry. The emergence of innovative genome editing tools, which allow easier manipulation of genomic DNA, has brought in a new phase in therapeutic development and disease detection, which derives the growth in rare disease genome editing industry. Consequently, service providers now have a profitable opportunity to tap previously unexplored areas in this field. Moreover, increasing government funding, growing production of genetically modified crops, and a rising number of genomics projects are expected to drive market growth.
Many companies are entering into licensing agreements with technology developers to strengthen their market presence, while key players are engaged in strategic initiatives like acquisitions and partnerships to expand their global presence. For instance, in February 2024, Precision BioSciences granted Caribou Biosciences a non-exclusive, global license to use its patented technology for targeted insertion of exogenous antigen binding receptors into the TRAC gene locus of human T cells. This agreement includes upfront payment, royalties on product sales, and potential milestone payments.
Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes. Due to their time-consuming, ineffective, and labor-intensive nature, traditional genome editing methods are only partially capable of keeping pace with the rapidly evolving genome modification era. In addition, technology also provides transformative results in various fields, such as plant, animal, & cell line genetic engineering and drug development & monitoring, which results in growth of the market. Technology has the potential to investigate different gene combinations, control gene expression, and find the role of individual DNA bases.
Advancements in genomics and related technologies have significantly impacted crop genetics. Genomes and transcriptomes can now be sequenced for many crops. Major benefits of gene manipulation tools in agricultural sectors include the development of Genetically Modified (GM) plants/crops with various advanced features, such as increased crop productivity. They also help conserve biodiversity, reduce agricultural eco-footprint, mitigate climate change, and aid in alleviating poverty and hunger.
This product will be delivered within 1-3 business days.
The COVID-19 pandemic had a significant impact on the market, causing disruptions in several aspects of the market including clinical trial disruptions, supply chain challenges, and stringent regulations. Manufacturing & supply chains were also affected by lockdown measures, travel restrictions, and reduced workforce, leading to delays in the production & distribution of gene therapy products. Despite these challenges, companies in the genome editing industry have adjusted to the new normal by implementing adaptive measures and are expected to recover from the impact of COVID-19. The pandemic accelerated R&D activities in gene alteration technologies, specifically in response to the urgent need for effective treatments and vaccines for COVID-19. For example, researchers at Nanyang Technological University developed the VaNGuard (Variant Nucleotide Guard) diagnostic test in March 2021, which has the capability to detect SARS-CoV-2 strains with mutations. This advancement is anticipated to leverage the utilization of CRISPR genome editing technology.
The rapid evolution of CRISPR-based tools has significantly led to the expansion of the genome editing industry. The emergence of innovative genome editing tools, which allow easier manipulation of genomic DNA, has brought in a new phase in therapeutic development and disease detection, which derives the growth in rare disease genome editing industry. Consequently, service providers now have a profitable opportunity to tap previously unexplored areas in this field. Moreover, increasing government funding, growing production of genetically modified crops, and a rising number of genomics projects are expected to drive market growth.
Many companies are entering into licensing agreements with technology developers to strengthen their market presence, while key players are engaged in strategic initiatives like acquisitions and partnerships to expand their global presence. For instance, in February 2024, Precision BioSciences granted Caribou Biosciences a non-exclusive, global license to use its patented technology for targeted insertion of exogenous antigen binding receptors into the TRAC gene locus of human T cells. This agreement includes upfront payment, royalties on product sales, and potential milestone payments.
Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes. Due to their time-consuming, ineffective, and labor-intensive nature, traditional genome editing methods are only partially capable of keeping pace with the rapidly evolving genome modification era. In addition, technology also provides transformative results in various fields, such as plant, animal, & cell line genetic engineering and drug development & monitoring, which results in growth of the market. Technology has the potential to investigate different gene combinations, control gene expression, and find the role of individual DNA bases.
Advancements in genomics and related technologies have significantly impacted crop genetics. Genomes and transcriptomes can now be sequenced for many crops. Major benefits of gene manipulation tools in agricultural sectors include the development of Genetically Modified (GM) plants/crops with various advanced features, such as increased crop productivity. They also help conserve biodiversity, reduce agricultural eco-footprint, mitigate climate change, and aid in alleviating poverty and hunger.
Global Genome Editing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The report has segmented the global genome editing market report based on technology, delivery method, application, mode, end use, and region:Technology Outlook (Revenue, USD Million, 2021-2033)
- (CRISPR)/Cas9
- TALENs/MegaTALs
- ZFN
- Meganucleases
- Others
Delivery Method Outlook (Revenue, USD Million, 2021-2033)
- Ex-vivo
- In-vivo
Application Outlook (Revenue, USD Million, 2021-2033)
- Genetic Engineering
- Clinical Applications
Mode Outlook (Revenue, USD Million, 2021-2033)
- Contract
- In-house
End Use Outlook (Revenue, USD Million, 2021-2033)
- Biotechnology and pharmaceutical companies
- Academic and government research institutes
- Contract research organizations
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- MEA
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Genome Editing Market Variables, Trends & Scope
Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis
Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis
Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis
Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis
Chapter 8. Genome Editing Market: End Use Estimates & Trend Analysis
Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Genome Editing market report include:- Merck KGaA
- Takara Bio Inc.
- Revvity, Inc.
- Danaher Corporation
- GenScript
- New England Biolabs
- Lonza
- Thermo Fisher Scientific, Inc.
- Charles River Laboratories
- Eurofins Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 11.37 Billion |
| Forecasted Market Value ( USD | $ 39.81 Billion |
| Compound Annual Growth Rate | 17.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
